Disease · MONDO_0008867
Comparisons in its trials15
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 15 of 15
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Corticosteroids vs Placebo: serious adverse events | 57 of 70 | 56 of 70 | 140 | NCT00294684 | Trial comparisons |
| Corticosteroids vs Placebo: Presence of Ascites at 12 Months | 5 of 52 | 3 of 47 | 99 | NCT00294684 | Trial comparisons |
| Corticosteroids vs Placebo: Presence of Ascites at 24 Months | 1 of 42 | 3 of 43 | 85 | NCT00294684 | Trial comparisons |
Double Blind - Maralixibat vs Double Blind - Placebo: Proportion of Participants Observed to Develop Clinically Evident Portal Hypertension Defined as Splenomegaly and Thrombocytopenia (Platelet Count <150 x 109/L) or Clinically Evident Ascites or Endoscopic Evidence of Esophageal or Gastric Varices. | 3 of 40 | 4 of 35 | 75 | NCT04524390 | Trial comparisons |
| Double Blind - Maralixibat vs Double Blind - Placebo: Proportion of Participants With Mean TSB Levels <2 mg/dL Through Week 26 | 24 of 40 | 20 of 35 | 75 | NCT04524390 | Trial comparisons |
Double Blind - Maralixibat vs Double Blind - Placebo: Proportion of Participants Observed to Have a Liver-related Clinical Event Transplantation, Liver Decompensation, Discontinuations Due to Liver Related Events, or Death. | 8 of 40 | 7 of 35 | 75 | NCT04524390 | Trial comparisons |
| Double Blind - Maralixibat vs Double Blind - Placebo: Proportion of Participants With Mean TSB Levels ≤1.2 mg/dL | 23 of 40 | 18 of 35 | 75 | NCT04524390 | Trial comparisons |
| Double Blind - Maralixibat vs Double Blind - Placebo: Proportion of Participants With Mean sBA Levels ≤40 mmol/L | 10 of 40 | 7 of 35 | 75 | NCT04524390 | Trial comparisons |
| Double Blind - Maralixibat vs Double Blind - Placebo: Proportion of Participants Undergoing Liver Transplantation or Death | 5 of 40 | 3 of 35 | 75 | NCT04524390 | Trial comparisons |
| Maralixibat: ALGS vs Maralixibat: PFIC: deaths from any cause | 1 of 40 | 0 of 12 | 52 | NCT04168385 | Trial comparisons |
| Maralixibat: ALGS vs Maralixibat: PFIC: serious adverse events | 10 of 40 | 3 of 12 | 52 | NCT04168385 | Trial comparisons |
| Pentoxifylline - Group 1 vs Group 2: Number of Participants Achieving Zero or Positive Weight Z-scores 12 Weeks After Starting PTX Therapy | 0 of 8 | 0 of 1 | 9 | NCT01774487 | Trial comparisons |
| Pentoxifylline - Group 1 vs Pentoxifylline - Group 2: Number of Participants With Normal Serum Conjugated Bilirubin Levels 12 Weeks After Starting PTX (Pentoxifylline) Therapy | 6 of 8 | 0 of 1 | 9 | NCT01774487 | Trial comparisons |
| Pentoxifylline - Group 1 (Treatment Starts 3-5 Days After Kasai Portoenterostomy) vs Pentoxifylline - Group 2 (Patient Diagnosed Too Late for Kasai Portoenterostomy): deaths from any cause | 0 of 8 | 0 of 1 | 9 | NCT01774487 | Trial comparisons |
| Pentoxifylline - Group 1 (Treatment Starts 3-5 Days After Kasai Portoenterostomy) vs Pentoxifylline - Group 2 (Patient Diagnosed Too Late for Kasai Portoenterostomy): serious adverse events | 6 of 8 | 1 of 1 | 9 | NCT01774487 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0008867/comparisons